X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ABUS

Closed

Arbutus Biopharma Corp

3.18
+0.09 (+2.91%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.09
Day's Range: 3.06 - 3.23
Send
When Written:
 
3.03
Arbutus Biopharma Corp is a biopharmaceutical company focused on discovering, developing, and commercializing a range of therapies for the treatment of viral diseases. The company is headquartered in Warminster, Pennsylvania, and has additional offices in Burnaby, British Columbia, Canada.

Arbutus Biopharma's pipeline includes several drug candidates for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV). The company's lead product candidate, ARB-1467, is a RNA interference (RNAi) therapeutic being developed for the treatment of chronic HBV infection.

The company also has partnerships and collaborations with several pharmaceutical companies, including Roivant Sciences, Alexion Pharmaceuticals, and Gritstone Oncology, among others.

Arbutus Biopharma was founded in 2008 as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in 2015. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol ABUS.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X